Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: A single institution experience Journal Article


Authors: Voss, M. H.; Lunning, M. A.; Maragulia, J. C.; Papadopoulos, E. B.; Goldberg, J.; Zelenetz, A. D.; Horwitz, S. M.
Article Title: Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: A single institution experience
Abstract: Introduction: Hepatosplenic T-cell lymphoma is a rare form of extranodal non-Hodgkin lymphoma, first recognized as a distinct entity in the Revised European-American Lymphoma classification. Typical presentation includes lymphomatous infiltration of spleen and liver, and peripheral lymphadenopathy is rarely seen. The prognosis is almost uniformly poor, and there are no prospective studies of treatment of HSTCL. Patients and Methods: For this report, we conducted a retrospective review of all pts who underwent treatment for HSTCL at our institution. Individual chart review was performed to report clinical presentation, management, and outcome. Results: We identified 14 pts with HSTCL managed at our center, 7 of which remain alive with median follow-up of 65.6 months. Six of 7 received alternative induction chemotherapy regimens such as ICE (ifosfamide, carboplatin, etoposide) or IVAC (ifosfamide, etoposide, high-dose cytarabine) as opposed to CHOP and all surviving pts had proceeded to undergo either autologous or allogeneic SCT. Conclusion: Our results suggest that use of non-CHOP induction regimen and early use of high dose therapy and SCT consolidation may translate to improved survival for pts with HSTCL. © 2013 Elsevier Inc.
Keywords: adolescent; adult; cancer survival; child; clinical article; treatment outcome; middle aged; retrospective studies; young adult; busulfan; fludarabine; prednisone; clinical feature; doxorubicin; cancer combination chemotherapy; liver neoplasms; cancer patient; combined modality therapy; cytarabine; drug megadose; follow up; follow-up studies; carboplatin; etoposide; antineoplastic combined chemotherapy protocols; cyclophosphamide; melphalan; vincristine; hematopoietic stem cell transplantation; medical record review; retrospective study; carmustine; ifosfamide; thiotepa; cancer regression; t cell lymphoma; lymphoma, t-cell; whole body radiation; graft versus host reaction; allogeneic hematopoietic stem cell transplantation; immunosuppressive treatment; autologous hematopoietic stem cell transplantation; alemtuzumab; pentostatin; splenic neoplasms; induction chemotherapy; thymocyte antibody; mercaptopurine; peripheral; early intervention; hepatosplenic t cell lymphoma; infliximab; adalimumab; long term survival; tcr gamma-delta
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 13
Issue: 1
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2013-02-01
Start Page: 8
End Page: 14
Language: English
DOI: 10.1016/j.clml.2012.09.002
PROVIDER: scopus
PUBMED: 23107915
PMCID: PMC4056251
DOI/URL:
Notes: --- - "Export Date: 1 March 2013" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Matthew Alexander Lunning
    26 Lunning
  2. Steven M Horwitz
    368 Horwitz
  3. Martin Henner Voss
    130 Voss
  4. Andrew D Zelenetz
    561 Zelenetz